GLT-1 upregulation impairs prepulse inhibition of the startle reflex in adult rats

GLIA

Volumn 57, Issue 7, 2009, Pages 703-713

  Bellesi, Michele ^a   Melone, Marcello ^a   Gubbini, Alessandro ^a   Battistacci, Silvia ^a   Conti, Fiorenzo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Ceftriaxone; Dihydrokainate; Glutamate; Glutamate transporters; PPI; Sensorimotor gating

Indexed keywords

CEFTRIAXONE; DIHYDROKAINIC ACID; SODIUM CHLORIDE; VESICULAR GLUTAMATE TRANSPORTER 1;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY THRESHOLD; CONTROLLED STUDY; FRONTAL CORTEX; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE MAGNITUDE; STARTLE REFLEX; UPREGULATION;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; CEFTRIAXONE; EXCITATORY AMINO ACID TRANSPORTER 2; HABITUATION, PSYCHOPHYSIOLOGIC; IMMUNOHISTOCHEMISTRY; KAINIC ACID; MALE; MICROSCOPY, CONFOCAL; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; UP-REGULATION;

EID: 66249121722     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20798     Document Type: Article

References (99)

1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
2. Amargos-Bosch M, Adell A, Artigas F. 2007. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. J Neurochem 102:550-561.
3. Andreasen NC. 1997. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology. Science 275:1586-1593.
4. Andreasen NC. 2000. Schizophrenia: The fundamental questions. Brain Res Brain Res Rev 31:106-112.
5. Anis NA, Berry SC, Burton NR, Lodge D. 1983. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565-575.
6. Antonova I, Arancio O, Trillat AC, Wang HG, Zablow L, Udo H, Kandel ER, Hawkins RD. 2001. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science 294:1547-1550.
7. Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG. 1994. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14:5559-5569.
8. Barbon A, Fumagalli F, La Via L, Caracciolo L, Racagni G, Riva AM, Barlati S. 2007. Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex. Exp Neurol 208:54-62.
9. Beal DM, Hudson B, Zaiac M. 1986. Amoxacillin-induced psychosis? Am J Psychiatry 143:255-256.
10. Beneyto M, Meador-Woodruff JH. 2006. Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60:585-598.
11. Berger UV, DeSilva TM, Chen W, Rosenberg PA. 2005. Cellular and subcellular mRNA localization of glutamate transporter isoforms GLT1a and GLT1b in rat brain by in situ hybridization. J Comp Neurol 492:78-89.
12. Bozdagi O, Shan W, Tanaka H, Benson DL, Huntley GW. 2000. Increasing numbers of synaptic puncta during late-phase LTP: N-cadherin is synthesized, recruited to synaptic sites, and required for potentiation. Neuron 28:245-259.
13. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
14. Braff DL, Geyer MA. 1990. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188.
15. Braff DL, Geyer MA, Swerdlow NR. 2001. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258.
16. Braff DL, Grillon C, Geyer MA. 1992. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215.
17. Braff DL, Light GA, Swerdlow NR. 2007. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61:1204-1207.
18. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. 1978. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343.
19. Bragina L, Melone M, Fattorini G, Torres-Ramos M, Vallejo-Illarramendi A, Matute C, Conti F. 2006. GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation. J Neurochem 99:134-141.
20. Brody SA, Conquet F, Geyer MA. 2003. Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci 18:3361-3366.
21. Brody SA, Dulawa SC, Conquet F, Geyer MA. 2004. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9:35-41.
22. Brody SA, Geyer MA. 2004. Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res 6:79-90.
23. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237-260.
24. Castner SA, Goldman-Rakic PS, Williams GV. 2004. Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 174:111-125.
25. Chen W, Mahadomrongkul V, Berger UV, Bassan M, DeSilva T, Tanaka K, Irwin N, Aoki C, Rosenberg PA. 2004. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J Neurosci 24:1136-1148.
26. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, Kim SJ, Park DK, Jung KH, Song EC, Lee SK, Kim M, Roh JK. 2007. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 38:177-182.
27. Conti F, Weinberg RJ. 1999. Shaping excitation at glutamatergic synapses. Trends Neurosci 22:451-458.
28. Coyle JT. 2004. The GABA-glutamate connection in schizophrenia: Which is the proximate cause? Biochem Pharmacol 68:1507-1514.
29. Coyle JT. 2006. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384.
30. Danbolt NC. 2001. Glutamate uptake. Prog Neurobiol 65:1-105.
31. Danbolt NC, Pines G, Kanner BI. 1990. Purification and reconstitution of the sodium- and potassium-coupled glutamate transport glycoprotein from rat brain. Biochemistry 29:6734-6740.
32. Dawson ME, Schell AM, Hazlett EA, Nuechterlein KH, Filion DL. 2000. On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Res 96:187-197.
33. Deng X, Shibata H, Ninomiya H, Tashiro N, Iwata N, Ozaki N, Fukumaki Y. 2004. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 6:4-21.
34. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, Snouwaert JN, Koller BH. 2004. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153:507-519.
35. Ellenbroek BA, Geyer MA, Cools AR. 1995. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J Neurosci 15:7604-7611.
36. Fattorini G, Melone M, Bragia L, Candiracci C, Cozzi A, Pellegrini Giampietro DE, Torres-Ramos M, Pérez-Samartín A, Matute C, Conti F. 2008. GLT-1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine. Glia 56:1320-1327.
37. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. 2005. Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 5:566-571.
38. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. 2001. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 156:117-154.
39. Geyer MA, McIlwain KL, Paylor R. 2002. Mouse genetic models for prepulse inhibition: An early review. Mol Psychiatry 7:1039-1053.
40. Geyer MA, Swerdlow NR. 1998. Measurement of startle response, prepulse inhibition, and habituation. In: Crawley JN, Skolnick P, editors. Current protocols in neuroscience. New York: Wiley. pp 8.7.1-8.7.157.
41. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. 2007. A placebo-controlled add-on Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology 33:465-472.
42. Grauer SM, Marquis KL. 1999. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology (Berl) 141:405-412.
43. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH. 2005. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57:123-131.
44. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ, Gallop RJ, Arnold SE. 2006. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12:824-828.
45. Ilechukwu ST. 1990. Acute psychotic reactions and stress response syndromes following intramuscular aqueous procaine penicillin. Br J Psychiatry 156:554-559.
46. Javitt DC. 2007. Glutamate and schizophrenia: Phencyclidine, N -methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108.
47. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. 1980. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382.
48. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. 2006. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11:737-747.
49. Lawrie S, Johnstone E, Weinberger D. 2004. Schizophrenia. From neuroimaging to neuroscience. Oxford, New York: Oxford University Press.
50. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li XM, Coyle JT, Huganir RL, Heckers S, Konradi C. 2000. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20:4011-4020.
51. Lewis DA, Gonzalez-Burgos G. 2006. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016-1022.
52. Lewis DA, Moghaddam B. 2006. Cognitive dysfunction in schizophrenia: Convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63:1372-1376.
53. Lipina T, Weiss K, Roder J. 2007. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology 32:745-756.
54. Lipski J, Wan CE, Bai JZ, Pi R, Li D, Donnelly D. 2007. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 146:617-629.
55. Mansbach RS, Geyer MA. 1989. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308.
56. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR. 1999. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21:28-39.
57. Matute C, Melone M, Vallejo-Illarramendi A, Conti F. 2005. Increased expression of the astrocytic glutamate transporter GLT-1 in the pre-frontal cortex of schizophrenics. Glia 49:451-455.
58. McCullumsmith RE, Meador-Woodruff JH. 2002. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26:368-375.
59. McDonald CA, Addis S. 2003. Cephalosporin-induced psychosis. Aust N Z J Psychiatry 37:627-628.
60. McGhie A, Chapman J. 1961. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103-116.
61. Melone M, Bellesi M, Conti F. 2009. Synaptic localization of GLT-1a in the rat somatic sensory cortex. Glia 57:108-117.
62. Melone M, Burette A, Weinberg RJ. 2005. Light microscopic identification and immunocytochemical characterization of glutamatergic synapses in brain sections. J Comp, Neurol 492:495-509.
63. Melone M, Bragina L, Conti F. 2003. Clozapine-induced reduction of glutamate transport is not mediated by GLAST and EAACL Mol Psychiatry 8:12-13.
64. Melons M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, Cozzi A, Pellegrini-Giampietro DE, Rothstein JD, Conti F. 2001. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 6:380-386.
65. Minassian A, Feifel D, Perry W. 2007. The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophr Res 89:225-231.
66. Minelli A, Barbaresi P, Reimer RJ, Edwards RH, Conti F. 2001. The glial glutamate transporter GLT-1 is localized both in the vicinity of and at distance from axon terminals in the rat cerebral cortex. Neuroscience 108:51-59.
67. Mirnics K , Middleton FA, Marquez A, Lewis DA, Levitt P. 2000. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28:53-67.
68. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
69. Noga JT, Wang H. 2002. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 45:250-258.
70. O'Connor JA, Hemby SE. 2007. Elevated GRIA1 mRNA expression in Layer II/ III and V pyramidal cells of the DLPFC in schizophrenia. Schizophr Res 97:277-288.
71. O'Connor JA, Muly EC, Arnold SE, Heraby SE. 2007. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophr Res 90:28-40.
72. Ouyang YB, Voloboueva LA, Xu LJ, Giffard RG. 2007. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J Neurosci 27:4253-4560.
73. Porter RH, Eastwood SL, Harrison PJ. 1997. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 751:217-231.
74. Ralph RJ, Paulus MP, Geyer MA. 2001. Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther 298:148-155.
75. Rao R. 1999. Penicillin psychosis in later life: Hoigne's syndrome revisited. J Neuropsychiatry Clin Neurosci 11:517-518.
76. Rebuelto M, Ambros L, Rubio M. 2003. Daily variations in ceftriaxone pharmacokinetics in rats. Antimicrob Agents Chemother 47:809-812.
77. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JF, Welty DF. 1996. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686.
78. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW. 1994. Localization of neuronal and glial glutamate transporters. Neuron 13:713-725.
79. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77.
80. Shao L, Vawter MP. 2008. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry 64:89-97.
81. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. 2001. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158:1393-1399.
82. Stell IM, Ojo OA. 1996. Amoxycillin-induced hallucinations - A variant of Hoigne's syndrome? Br J Clin Pract 50:279.
83. Steullet P, Neijt HC, Cuenod M, Do KQ. 2006. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience 137:807-819.
84. Sullivan R, Rauen T, Fischer F, Wiessner M, Grewer C, Bicho A, Pow DV. 2004. Cloning, transport properties, and differential localization of two splice variants of GLT-1 in the rat CNS: Implications for CNS glutamate homeostasis. Glia 45:155-169.
85. Swerdlow NR, Braff DL, Geyer MA. 2000. Animal models of deficient sensorimotor gating: What we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11:185-204.
86. Swerdlow NR, Braff DL, Taaid N, Geyer MA. 1994. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154.
87. Swerdlow NR, Geyer MA, Braff DL. 2001. Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215.
88. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. 2006. Startle gating deficits in a large cohort of patients with schizophrenia: Relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63:1325-1335.
89. Tononi G, Edelman GM. 2000. Schizophrenia and the mechanisms of conscious integration. Brain Res Brain Res Rev 31:391-400.
90. Torres GE, Amara SG. 2007. Glutamate and monoamine transporters: New visions of form and function. Curr Opin Neurobiol 17:304-312.
91. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. 2007. Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull 33:69-94.
92. Tzingounis AV, Wadiche JI. 2007. Glutamate transporters: Confining runaway excitation by shaping synaptic transmission. Nat Rev Neurosci 8:935-947.
93. Uhlhaas PJ, SingerW. 2006. Neural synchrony in brain disorders: Relevance for cognitive dysfunctions and pathophysiology.Neuron 52:155-168.
94. Vallejo-Illarramendi A, Torres-Ramos M, Melone M, Conti F, Matute C. 2005. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50:276-279.
95. Venables PH. 1960. The effect of auditory and visual stimulation on the skin potential response of schizophrenics. Brain 83:77-92.
96. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J Neurosci 16:373-379.
97. Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K, Sprengel R, Celikel T, Daws LC, Holmes A. 2007. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 13:631-640.
98. Williamson P. 2006. Mind, brain, and schizophrenia. Oxford, New York: Oxford University Press.
99. Winterer G, Weinberger DR. 2004. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27:683-690.